Pricing Log in Create free account

InflaRx N.V. (IFRX) vs Sol-Gel Technologies Ltd. (SLGL)

InflaRx N.V. and Sol-Gel Technologies Ltd. are both Biotechnology companies. InflaRx N.V. and Sol-Gel Technologies Ltd. are of similar size ($224.9M and $212.2M). InflaRx N.V. grew revenue faster over the last twelve months: −83.4% against −92.5%. InflaRx N.V. has the higher net margin (0.00% vs −910.1%) and the higher return on invested capital (0.00% vs −6,630.2%). Across the 16 metrics below, InflaRx N.V. leads on 10 and Sol-Gel Technologies Ltd. on 6.

Valuation

Metric IFRX SLGL Biotechnology median
P/E n/m n/m 8.50
P/S 5,075.70 117.08 9.71
P/B 0.91 4.37 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.71 n/m 0.64
EV/Sales (1,061.22) 126.78 9.21
Earnings yield (43.94%) (8.78%) (33.15%)
Free cash flow yield (17.60%) (10.12%) (25.50%)

Profitability

Metric IFRX SLGL Biotechnology median
Gross margin (26,762.42%) 100.00% 65.16%
Operating margin 0.00% (986.96%) 0.00%
Net margin 0.00% (910.14%) 0.00%
Free cash flow margin 0.00% (1,185.18%) 0.00%
Return on equity (38.71%) (40.85%) (56.36%)
Return on assets (32.75%) (35.11%) (48.04%)
Return on invested capital 0.00% (6,630.24%) 0.00%

Growth

Metric IFRX SLGL Biotechnology median
Revenue growth (TTM) (83.39%) (92.50%) 6.02%
EPS growth (last fiscal year) 9.41% 42.37% 30.26%
Revenue growth, 5-year CAGR — 17.19% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IFRX SLGL Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 8.22 10.37 4.72
Net debt to EBITDA 0.97 3.23 0.96

Dividend

Metric IFRX SLGL Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric IFRX SLGL Biotechnology median
Market cap 212.21m 224.92m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack